S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   415.91 (-1.77%)
AAPL   164.25 (-1.67%)
MSFT   398.79 (-1.36%)
META   482.93 (-3.76%)
GOOGL   153.41 (-1.67%)
AMZN   174.62 (-2.57%)
TSLA   148.76 (-0.78%)
NVDA   805.31 (-4.89%)
AMD   147.96 (-4.59%)
NIO   3.81 (-4.75%)
BABA   68.52 (-0.52%)
T   16.34 (+0.06%)
F   12.09 (+0.25%)
MU   106.97 (-4.43%)
GE   148.61 (-2.83%)
CGC   8.01 (+2.30%)
DIS   111.29 (-1.01%)
AMC   3.18 (+8.90%)
PFE   25.80 (+1.61%)
PYPL   61.77 (-0.53%)
XOM   119.89 (+1.16%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   415.91 (-1.77%)
AAPL   164.25 (-1.67%)
MSFT   398.79 (-1.36%)
META   482.93 (-3.76%)
GOOGL   153.41 (-1.67%)
AMZN   174.62 (-2.57%)
TSLA   148.76 (-0.78%)
NVDA   805.31 (-4.89%)
AMD   147.96 (-4.59%)
NIO   3.81 (-4.75%)
BABA   68.52 (-0.52%)
T   16.34 (+0.06%)
F   12.09 (+0.25%)
MU   106.97 (-4.43%)
GE   148.61 (-2.83%)
CGC   8.01 (+2.30%)
DIS   111.29 (-1.01%)
AMC   3.18 (+8.90%)
PFE   25.80 (+1.61%)
PYPL   61.77 (-0.53%)
XOM   119.89 (+1.16%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   415.91 (-1.77%)
AAPL   164.25 (-1.67%)
MSFT   398.79 (-1.36%)
META   482.93 (-3.76%)
GOOGL   153.41 (-1.67%)
AMZN   174.62 (-2.57%)
TSLA   148.76 (-0.78%)
NVDA   805.31 (-4.89%)
AMD   147.96 (-4.59%)
NIO   3.81 (-4.75%)
BABA   68.52 (-0.52%)
T   16.34 (+0.06%)
F   12.09 (+0.25%)
MU   106.97 (-4.43%)
GE   148.61 (-2.83%)
CGC   8.01 (+2.30%)
DIS   111.29 (-1.01%)
AMC   3.18 (+8.90%)
PFE   25.80 (+1.61%)
PYPL   61.77 (-0.53%)
XOM   119.89 (+1.16%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   415.91 (-1.77%)
AAPL   164.25 (-1.67%)
MSFT   398.79 (-1.36%)
META   482.93 (-3.76%)
GOOGL   153.41 (-1.67%)
AMZN   174.62 (-2.57%)
TSLA   148.76 (-0.78%)
NVDA   805.31 (-4.89%)
AMD   147.96 (-4.59%)
NIO   3.81 (-4.75%)
BABA   68.52 (-0.52%)
T   16.34 (+0.06%)
F   12.09 (+0.25%)
MU   106.97 (-4.43%)
GE   148.61 (-2.83%)
CGC   8.01 (+2.30%)
DIS   111.29 (-1.01%)
AMC   3.18 (+8.90%)
PFE   25.80 (+1.61%)
PYPL   61.77 (-0.53%)
XOM   119.89 (+1.16%)
Free Trial

Xtant Medical (XTNT) Stock Forecast & Price Target

→ Don’t expose yourself to stocks during the week (From DTI) (Ad)
Free XTNT Stock Alerts
$0.89
+0.06 (+6.77%)
(As of 12:13 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort Interest

Xtant Medical Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 2 Analyst Ratings

Analysts' Consensus Price Target

$1.60
78.99% Upside
High Forecast$2.00
Average Forecast$1.60
Low Forecast$1.20
TypeCurrent Forecast
4/20/23 to 4/19/24		1 Month Ago
3/21/23 to 3/20/24		3 Months Ago
1/20/23 to 1/20/24		1 Year Ago
4/20/22 to 4/20/23
Consensus Rating
Buy
Buy
Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
 N/A
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
 N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
 N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
 N/A
Consensus Price Target$1.60$1.60$1.60N/A
Predicted Upside78.99% Upside40.35% Upside40.35% UpsideN/A
Get Xtant Medical Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for XTNT and its competitors with MarketBeat's FREE daily newsletter.

XTNT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

XTNT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Xtant Medical Stock vs. The Competition

TypeXtant MedicalMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside91.11% Upside928.53% Upside12.31% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/5/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$2.00+52.67%
7/11/2023Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$1.00 ➝ $1.20+50.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 12:34 PM ET.

XTNT Price Target - Frequently Asked Questions

What is Xtant Medical's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Xtant Medical stock is Buy based on the current 2 buy ratings for XTNT. The average twelve-month price prediction for Xtant Medical is $1.60 with a high price target of $2.00 and a low price target of $1.20. Learn more on XTNT's analyst rating history.

Do Wall Street analysts like Xtant Medical more than its competitors?

Analysts like Xtant Medical more than other Medical companies. The consensus rating for Xtant Medical is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how XTNT compares to other companies.

Does Xtant Medical's stock price have much upside?

According to analysts, Xtant Medical's stock has a predicted upside of 40.35% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NYSEAMERICAN:XTNT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
How Biden has already won 2024
Porter & Company
My biggest AI fear
Paradigm Press
Options trading has suddenly become more reliable.
Eagle Publishing